Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Acquired by Cerity Partners LLC

Cerity Partners LLC grew its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 4,953.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 823,134 shares of the biopharmaceutical company's stock after buying an additional 806,846 shares during the period. Cerity Partners LLC owned 0.72% of Fate Therapeutics worth $1,358,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Barclays PLC lifted its holdings in Fate Therapeutics by 245.3% in the third quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company's stock valued at $1,485,000 after acquiring an additional 301,389 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Fate Therapeutics by 18.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company's stock valued at $6,431,000 after purchasing an additional 283,080 shares during the period. BIT Capital GmbH purchased a new stake in Fate Therapeutics during the fourth quarter worth $408,000. Monaco Asset Management SAM grew its position in Fate Therapeutics by 138.0% during the fourth quarter. Monaco Asset Management SAM now owns 327,671 shares of the biopharmaceutical company's stock valued at $541,000 after buying an additional 190,000 shares during the period. Finally, Aristides Capital LLC purchased a new position in Fate Therapeutics in the fourth quarter valued at $166,000. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Fate Therapeutics Stock Performance

Shares of FATE stock traded up $0.03 on Wednesday, hitting $1.40. 1,011,536 shares of the stock traded hands, compared to its average volume of 2,373,613. Fate Therapeutics, Inc. has a twelve month low of $0.66 and a twelve month high of $5.92. The firm's 50-day moving average price is $1.04 and its two-hundred day moving average price is $1.74. The stock has a market capitalization of $160.95 million, a PE ratio of -0.85 and a beta of 2.41.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.13. The business had revenue of $1.86 million during the quarter, compared to analysts' expectations of $1.57 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. On average, equities research analysts anticipate that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on FATE shares. StockNews.com lowered Fate Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, March 11th. Wells Fargo & Company reduced their target price on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. Stifel Nicolaus dropped their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research note on Thursday, March 6th. Wedbush restated a "neutral" rating and set a $5.00 price objective on shares of Fate Therapeutics in a research report on Thursday, March 6th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $5.43.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.